Expanding North American distribution channels and bringing alcohol product manufacturing in-house through the acquisition of ハイドロックス・ラボラトリーズ社
First written in FY2022-Q3. 5 of 8 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「ハイドロックス・ラボラトリーズ社, which manufactures and sells medical disinfectants and other products, continued to perform well.」
ハイドロックス・ラボラトリーズ社's contribution to the increase in revenue in the North American business has continued since its acquisition. - FY2024RestatedAnnual report
「ハイドロックス・ラボラトリーズ社, which manufactures and sells medical disinfectants and other products, continued to perform well and made a significant contribution to the increase in revenue.」
ハイドロックス・ラボラトリーズ社's contribution to the increase in revenue in the North American business has continued since its acquisition. - FY2024-Q3RestatedAnnual report
「ハイドロックス・ラボラトリーズ社, which manufactures and sells medical disinfectants and other products, continued to perform well and made a significant contribution to the increase in revenue.」
The company has reconfirmed that ハイドロックス・ラボラトリーズ社 continued to perform well and made a significant contribution to the increase in revenue in the Americas. - FY2024-Q2RestatedAnnual report
「ハイドロックス・ラボラトリーズ社, which manufactures and sells medical disinfectants and other products, continued to perform well and made a significant contribution to the increase in revenue.」
The company has reconfirmed that ハイドロックス・ラボラトリーズ社 continued to perform well and made a significant contribution to the increase in revenue in the Americas. - FY2024-Q1RestatedAnnual report
「ハイドロックス・ラボラトリーズ社, which manufactures and sells medical disinfectants and other products, continued to perform well and made a significant contribution to the increase in revenue.」
It was stated that ハイドロックス・ラボラトリーズ社, acquired to expand North American distribution channels and develop alcohol products and bring existing products in-house, continued to make a significant contribution to the increase in revenue in the Americas. - FY2023-Q2AdvancedAnnual report
「ハイドロックス・ラボラトリーズ社, which manufactures and sells medical disinfectants and other products and became a subsidiary in October 2021, made a significant contribution to the increase in revenue.」
ハイドロックス・ラボラトリーズ社, acquired to expand North American distribution channels and develop alcohol products and bring existing products in-house, made a significant contribution to the 90.0% increase in sales to external customers in the Americas. - FY2023-Q1AdvancedAnnual report
「ハイドロックス・ラボラトリーズ社, which manufactures and sells medical disinfectants and other products and became a subsidiary in October 2021, made a significant contribution to the increase in revenue.」
ハイドロックス・ラボラトリーズ社, acquired to expand North American distribution channels and develop alcohol products and bring existing products in-house, made a significant contribution to the increase in revenue in the Americas segment after its acquisition. - FY2022-Q3First statedAnnual report
「ハイドロックス・ラボラトリーズ社 is a pharmaceutical company founded in 1913 that manufactures and sells antiseptic alcohol preparations, disinfectant detergents and other products. The Mentholatum Company (US), a consolidated subsidiary, acquired its shares to expand distribution channels in North America, promote the development of alcohol preparations and bring existing products in-house. Date of business combination: 31 October 2021 Voting rights acquired: 100%」
The Mentholatum Company (US) acquired 100% of ハイドロックス・ラボラトリーズ社 on 31 October 2021 to expand distribution channels in North America and develop alcohol preparations and bring existing products in-house.